SERD drugs are pharmacologic agents that share a common mechanism (typically targeting Estrogen receptor). 0 are currently marketed, with 3 more in clinical development.

SERD

0 marketed 1 in Phase 3 2 in Phase 1

This page covers all SERD drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Estrogen receptor, Estrogen receptor alpha (ERα), mTOR.

Targets

Estrogen receptor · Estrogen receptor alpha (ERα) · mTOR

Phase 3 pipeline (1)

XZP-3287+Fulvestrant · Xuanzhu Biopharmaceutical Co., Ltd. · Oncology
XZP-3287+Fulvestrant is a combination of XZP-3287 and Fulvestrant, which works by inhibiting the estrogen receptor.

Phase 1 pipeline (2)

AZD9833 with anastrozole · AstraZeneca · Oncology
Estrogen receptor inhibitor
AZD9833 with everolimus · AstraZeneca · Oncology
mTOR inhibitor